Translated title of the contribution: Diagnostic and therapeutic aspects of growth hormone releasing factor

K. Von Werder, M. Losa, O. A. Muller

Research output: Contribution to journalArticlepeer-review


Growth hormone releasing factor (GRF) is the last hypophyseotropic neuro-hormone whose structure has been clarified. Contrary to all other neurohormones, the structure of which was found through research on numerous hypothalamic particles of sheep and pigs, GRF was extracted from human pancreatic tissue. Hypothalamic and ectopic GRF are identical. GRF plays an important physiologic role in the regulation of GH secretion. Somatostatin has mainly a modulation effect. Accordingly, lesions of the hypothalamus cause a growth hormone deficiency. The GRF test which can be done with 50 or 100 μg GRF enables the localization of the defect that has caused the GH deficiency. The GH shortage is due to lack of GRF in more than half of the cases of patients with idiopathic hypophyseal dwarfism. GRF substitution instead of growth hormone treatment is now possible. The GRF test is of no use for the diagnosis of acromegaly. In cases of established acromegaly GRF should be determined in the future in order to find the rare cases (less than 1%) of ectopic GRF hypersecretion, which require completely different treatment.

Translated title of the contributionDiagnostic and therapeutic aspects of growth hormone releasing factor
Original languageGerman
Pages (from-to)259-265
Number of pages7
Issue number5
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Diagnostic and therapeutic aspects of growth hormone releasing factor'. Together they form a unique fingerprint.

Cite this